IZEA Reports Q1 2024 Revenue of $7.0 million
May 15, 2024 16:01 ET
|
IZEA Worldwide, Inc.
ORLANDO, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the Creator Economy, reported its...
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024 16:01 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
May 15, 2024 16:01 ET
|
Eyenovia, Inc.
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the...
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024 16:01 ET
|
Apogee Therapeutics, LLC
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week...
United Fire Group, Inc. Declares a Common Stock Quarterly Cash Dividend of $0.16 per Share
May 15, 2024 16:01 ET
|
United Fire Group, Inc
CEDAR RAPIDS, IOWA , May 15, 2024 (GLOBE NEWSWIRE) -- Today, the Board of Directors of United Fire Group, Inc. (Nasdaq: UFCS) ("UFG") declared a common stock quarterly cash dividend of $0.16 per...
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
May 15, 2024 16:01 ET
|
Celcuity Inc.
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...
CSX Executive Vice President and Chief Financial Officer to Address Wolfe Research Global Transportation & Industrials Conference
May 15, 2024 16:01 ET
|
CSX Corporation
JACKSONVILLE, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Financial Officer, Sean Pelkey, will address the 17th Annual Wolfe Research Global...
Xometry Appoints Subir Dutt As Chief Sales Officer
May 15, 2024 16:01 ET
|
Xometry, Inc.
Xometry Appoints Subir Dutt As Chief Sales Officer
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
May 15, 2024 16:01 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Five Below, Inc. Announces First Quarter Fiscal 2024 Earnings Release and Conference Call Date
May 15, 2024 16:01 ET
|
Five Below, Inc.
PHILADELPHIA, PA, May 15, 2024 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality, extreme-value retailer for tweens, teens and beyond, today announced that its...